Lymphocyte trafficking into lymph nodes and Peyer's patches is mediated primarily by specifically differentiated venules, called high endothelial venules (HEVs), located in the tissue parenchyma. HEVs have a unique morphology and phenotype, which enables them to interact with circulating lymphocytes efficiently. That is, the HEV endothelial cells have a tall and plump appearance, and constitutively express multiple adhesion molecules and chemokines on their surface. These molecules can interact with cognate receptors on circulating lymphocytes, thereby mediating the stepwise and sequential lymphocyte adhesion and transendothelial migration (TEM) at the HEV endothelial luminal surface. This review summarizes the fine morphological aspects of the unique HEV endothelial cells, with special reference to the spatial distribution of the adhesion molecules and chemokines that regulate lymphocyte migration.

Download full-text PDF

Source
http://dx.doi.org/10.14670/HH-25.781DOI Listing

Publication Analysis

Top Keywords

hev endothelial
12
high endothelial
8
endothelial venules
8
lymph nodes
8
circulating lymphocytes
8
endothelial cells
8
adhesion molecules
8
molecules chemokines
8
endothelial
5
microanatomy lymphocyte-endothelial
4

Similar Publications

Tertiary lymphoid structures (TLS) are lymphoid formations that develop in non-lymphoid tissues during chronic inflammation, autoimmune diseases, and cancer. Accurate identification and quantification of TLS in tissue can provide crucial insights into the immune response of several disease processes including antitumor immune response. TLS are defined as aggregates of T cells, B cells and dendritic cells.

View Article and Find Full Text PDF

Background/aim: The dynamic interplay between cancer cells and the microenvironment involves a wide range of intricate relationships that evolve during different stages of tumor progression. Recent attention has focused on high endothelial venules (HEVs), specialized endothelial cells in tumors with a unique cuboidal shape similar to those in lymph nodes. Previous animal studies have shown that normalization of tumor angiogenesis through anti-VEGFR2 therapy promotes HEV formation.

View Article and Find Full Text PDF

Background: α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.

Materials And Methods: Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation.

View Article and Find Full Text PDF
Article Synopsis
  • Allergic fungal rhinosinusitis (AFRS) and eosinophilic chronic rhinosinusitis (ECRS) both involve nasal polyps but differ primarily in the presence of fungal infections in AFRS.
  • A study analyzed nasal polyps from patients with AFRS, ECRS, and non-ECRS to assess immune cell types, revealing that AFRS had more M2 macrophages compared to ECRS, which is linked to the fungal infection.
  • The findings underline the unique immune responses in AFRS versus ECRS, particularly the role of M2 macrophages in AFRS's development.
View Article and Find Full Text PDF

The presence of high endothelial venules (HEV) and tertiary lymphoid structures (TLS) in solid tumors is correlated with favorable prognosis and better responses to immune checkpoint blockade in many cancer types. Elucidation of the molecular mechanisms underlying intratumoral HEV and TLS formation and their contribution to antitumor responses may facilitate the development of improved treatment strategies. Lymphotoxin β receptor (LTβR) signaling is a critical regulator of lymph node organogenesis and can cooperate with antiangiogenic and immune checkpoint blockade treatment to augment tumor-associated HEV formation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!